These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17350312)

  • 1. Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies.
    Freeston J; Barkham N; Hensor E; Emery P; Fraser A
    Joint Bone Spine; 2007 Mar; 74(2):140-3. PubMed ID: 17350312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database.
    Arévalo M; Gratacós Masmitjà J; Moreno M; Calvet J; Orellana C; Ruiz D; Castro C; Carreto P; Larrosa M; Collantes E; Font P;
    Arthritis Res Ther; 2018 Oct; 20(1):221. PubMed ID: 30285828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of HLA-B27-positive enthesitis/spondylitis-related arthritis in Senegal, West Africa.
    Sabounji MM; Ndiaye A; Diallo S
    Pediatr Rheumatol Online J; 2024 Feb; 22(1):31. PubMed ID: 38424655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
    Barkham N; Keen HI; Coates LC; O'Connor P; Hensor E; Fraser AD; Cawkwell LS; Bennett A; McGonagle D; Emery P
    Arthritis Rheum; 2009 Apr; 60(4):946-54. PubMed ID: 19333933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER).
    Almodóvar R; Font P; Zarco-Montejo P; Collantes E; Mulero J; Gratacós J; Juanola X; Ariza R
    Clin Exp Rheumatol; 2011; 29(5):822-7. PubMed ID: 22011437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.
    Kim M; Won JY; Choi SY; Ju JH; Park YH
    Am J Ophthalmol; 2016 Oct; 170():32-40. PubMed ID: 27470062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to ankylosing spondylitis but not disease outcome is influenced by the level of HLA-B27 expression, which shows moderate variability over time.
    Cauli A; Dessole G; Vacca A; Porru G; Cappai L; Piga M; Bitti PP; Fiorillo MT; Sorrentino R; Carcassi C; Mathieu A
    Scand J Rheumatol; 2012 May; 41(3):214-8. PubMed ID: 22360441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ankylosing spondylitis functional and activity indices in clinical practice.
    Popescu C; Trandafir M; Bădică A; Morar F; Predeţeanu D
    J Med Life; 2014 Mar; 7(1):78-83. PubMed ID: 24653763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B27 is associated with reduced disease activity in axial spondyloarthritis.
    Rosenbaum JT; Weisman MH; Hamilton H; Shafer C; Aslanyan E; Howard RA; Ogle K; Reveille JD; Winthrop KL; Choi D
    Sci Rep; 2021 Jun; 11(1):12331. PubMed ID: 34112886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers.
    Saeed A; Khan M; Elmamoun M; Brady M; Morrissey S; Fraser AD
    Rheumatol Int; 2012 May; 32(5):1305-9. PubMed ID: 21286722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registry of the clinical characteristics of spondyloarthritis in a cohort of Egyptian population.
    Tayel MY; Soliman E; El Baz WF; El Labaan A; Hamaad Y; Ahmed MH
    Rheumatol Int; 2012 Sep; 32(9):2837-42. PubMed ID: 21879376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study.
    Wang KC; Sun YS; Tsai HC; Liao HT; Lai CC; Chen WS; Lu LY; Chen MH
    Mod Rheumatol; 2024 Aug; 34(5):1027-1035. PubMed ID: 38302085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
    Coates LC; Cawkwell LS; Ng NW; Bennett AN; Bryer DJ; Fraser AD; Emery P; Marzo-Ortega H
    Rheumatology (Oxford); 2008 Jun; 47(6):897-900. PubMed ID: 18403400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased level of HLA-B27 expression in ankylosing spondylitis patients compared with healthy HLA-B27-positive subjects: a possible further susceptibility factor for the development of disease.
    Cauli A; Dessole G; Fiorillo MT; Vacca A; Mameli A; Bitti P; Passiu G; Sorrentino R; Mathieu A
    Rheumatology (Oxford); 2002 Dec; 41(12):1375-9. PubMed ID: 12468816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis.
    Caso F; Costa L; Del Puente A; Rigante D; Selmi C; Fabbroni M; Scarpa R; Galeazzi M; Frediani B; Cantarini L
    Clin Exp Rheumatol; 2015; 33(3):411-3. PubMed ID: 25962691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis.
    Kviatkovsky MJ; Ramiro S; Landewé R; Dougados M; Tubach F; Bellamy N; Hochberg M; Ravaud P; Martin-Mola E; Awada H; Bombardier C; Felson D; Hajjaj-Hassouni N; Logeart I; Matucci-Cerinic M; van de Laar M; van der Heijde D
    J Rheumatol; 2016 Sep; 43(9):1680-6. PubMed ID: 27307522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaphorin 3A in Ankylosing Spondylitis.
    Liao HT; Lin YF; Chou CT; Tsai CY
    J Microbiol Immunol Infect; 2019 Feb; 52(1):151-157. PubMed ID: 28736223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.